Coherus BioSciences Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Coherus BioSciences's estimated annual revenue is currently $22.8M per year.
- Coherus BioSciences received $75.0M in venture funding in January 2019.
- Coherus BioSciences's estimated revenue per employee is $81,960
- Coherus BioSciences's total funding is $327.5M.
- Coherus BioSciences has 278 Employees.
- Coherus BioSciences grew their employee count by 15% last year.
- Coherus BioSciences currently has 22 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$27.6M||178||8%||N/A|
|The J. Craig Ve...||$33.3M||215||N/A||N/A|
What Is Coherus BioSciences?
Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Alan Herman||General Manager||Email Available|
|Francesca Civoli||Director, Preclinical Development||Email Available|
|Lee Mermelstein||Senior Vice President Manufacturing|
|Erik Wiberg||Executive Vice President, Corporate Development||Email Available|
|Juliana Reed||Vice President, Government Affairs||Email Available|
|Richard Boismenu||Vice President Of Product Development||Email Available|
|Joan Eggert||Senior Vice President, Transactions & Legal Affairs||Email Available|
|Sarita Jain||Vice President, Business Development||Email Available|
|Francie Lin||Sr Director, Commercial Analytics||Email Available|
|Jun Liu||Vice President Operations||Email Available|
Coherus BioSciences News
REDWOOD CITY, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective ...
BidaskClub cut shares of Coherus Biosciences (NASDAQ:CHRS) from a buy rating to a hold rating in a report released on Friday, BidAskClub ...
For its latest trading sesion, Coherus BioSciences, Inc. (CHRS) dropped by -2.8% – here is what that looked like (as of 2019-09-09): ...
Coherus BioSciences Funding
|2014-11-07||$85.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2015-03-31||$115.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2015-04-02||$138.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2019-01-08||$75.0M||Undisclosed||Healthcare Royalty Partners||Article|
Coherus BioSciences Executive Hires
|2014-04-29||Michael A. Fleming||SVP Commercial Strategy||Article|
|2014-05-13||Lisa M. Bell||SVP Global Regulatory Affairs||Article|
|2014-06-10||Vince R. Anicetti||SVP Global Quality||Article|
|2016-05-17||Patrick O?Brien||SVP Investor Relations||Article|
|2017-03-28||Erik Wiberg||vp Corporate Development||Article|
|2019-01-03||Darlene Horton||Chief Medical and Regulatory Affairs Officer||Article|
|2019-03-19||Thomas Fitzpatrick||Chief Legal Officer||Article|
Coherus BioSciences Staff Cuts
|Date||Number of Employees||Location||Reference|